A Study to Assess the Effect of CK-2127107 on Physical Fu... | NCT02662582

Name	Class
Cytokinetics	INDUSTRY

Label	Type	Description	Intervention Names
CK-2127107 1000 mg, then placebo	Experimental	Participants received CK-2127107 500 milligram (mg), orally, twice daily for 2 weeks in treatment period 1 followed by matching placebo orally, twice daily for 2 weeks in treatment period 2. A washout period of 2 weeks was maintained between the two treatment periods.	Drug: Reldesemtiv Drug: Placebo
Placebo, then CK-212710 1000 mg	Experimental	Participants received matching placebo orally, twice daily for 2 weeks in treatment period 1 followed by CK-2127107 500 mg in treatment period 2. A washout period of 2 weeks was maintained between the two treatment periods.	Drug: Reldesemtiv Drug: Placebo

Name	Type	Description	Arm Group Labels	Other Names
Reldesemtiv	Drug	Oral tablet	CK-2127107 1000 mg, then placebo Placebo, then CK-212710 1000 mg

Measure	Description	Time Frame
Change From Period Baseline at Week 2 in Constant Work Rate (CWR) Endurance Time Relative to Placebo	The CWR defines how long it takes until the participant reaches symptom limitations while simultaneously being monitored and is called "CWR time to intolerance," which determined the "CWR endurance time". Positive change indicates an improvement from baseline (i.e., a favorable outcome).	Baseline and week 2 of each treatment period

Measure	Description	Time Frame
Change From Period Baseline at Week 2 in Oxygen Uptake (VO2)	VO2 was defined as volume of O2 extracted from inspired air in a given period of time. VO2 was reported at isotime and peak exercise during CWR test.	Baseline and week 2 of each treatment period
Change From Period Baseline at Week 2 in Ventilation (VE)

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Subject has a body mass index (BMI) of 18-35 kg/m2 inclusive.
Subject must have all of the following:
- Clinical diagnosis of moderate to severe COPD, with a postbronchodilator FEV1/FVC ratio < 70% and 30% ≤ FEV1 < 65% predicted at screening. The predicted values for normal spirometry will be those recommended by the American Thoracic Society (ATS) / European Respiratory Society (ERS) [Miller et al, 2005].
- General stable health with no change in medication (including non-COPD agents and dietary aids/food supplements) within 2 weeks prior to screening, no systemic corticosteroid administration (topical or inhaled corticosteroids are allowed) within 6 weeks prior to screening, no exacerbations or hospitalization within 6 weeks prior to screening.
- Current or ex-smokers with a smoking history of at least 10 pack years.
- Grade of 2 or 3 on the Modified Medical Research Council (mMRC) Dyspnea Scale at screening:
  1. Grade 2: walks slower than people of the same age on the level because of breathlessness or has to stop for breath when walking at own pace on the level.
  2. Grade 3: stops for breath after walking about 100 meters or after a few minutes on the level.
Subject is able to complete technically acceptable respiratory muscle strength tests, spirometry, physical performance test and exercise tests.
Female subject must either:
- Be of non-child bearing potential: Postmenopausal (defined as at least 1 year without any menses) prior to screening, or documented surgically sterile.
- Or, if of childbearing potential: Agree not to try to become pregnant during the study and for 28 days after the last dose, and have a negative serum pregnancy test at screening, and, if heterosexually active, agree to consistently use 2 forms of highly-effective birth control (at least 1 of which must be a barrier method) starting at screening, throughout the study, and for 28 days after the last dose.
Female subject must agree not to breastfeed starting at screening and throughout the study and for 28 days after the last dose.
Female subject must not donate ova starting at screening, throughout the study and for 28 days after the last dose.
Male subject and their female spouse/partners who are of childbearing potential must be using highly effective form of contraception consisting of 2 forms of birth control (at least 1 of which must be a barrier method) starting at screening, and continuing throughout the study and for 90 days after the last dose.
Male subject must not donate sperm starting at screening, throughout the study and for 90 days after the last dose.
Subject agrees not to participate in another interventional study from screening through the follow-up visit (FUV) of the study.

Exclusion Criteria:

Subject has previously enrolled in a clinical study of CK-2127107.
Subject has any clinically significant abnormality following the investigator's review of the physical examination, ECG and protocol-defined clinical laboratory tests at screening. A significant abnormality is defined as an abnormality which, in the opinion of the investigator, may (i) put the subject at risk because of participation in the study, (ii) influence the results of the study or (iii) cause concern regarding the subject's ability to participate in the study.
Subject has any of the liver function tests (LFTs; i.e., aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase [ALP], γ-glutamyl transferase [GGT] and/or total bilirubin [TBL]) above 1.5 times the upper limit of normal (ULN) at screening. These assessments may be repeated once at the investigator's discretion (within the screening window).
Subject has an estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m2 by the Cockcroft-Gault equation at screening.
Subject has a serious cardiovascular disease, including a current New York Heart Association (NYHA) class III or IV congestive heart failure or clinically significant valvular disease, history of cardiac arrest, uncontrolled angina or arrhythmia, untreated serious conduction disorder (e.g., third-degree heart block), or acute myocardial ischemic condition suspected on the ECG at screening (e.g., ST-segment elevation, ST-segment depressions > 2 mm).
Subject has had a myocardial infarction or other acute coronary syndrome, major heart surgery (i.e., valve replacement or bypass surgery), stroke, deep vein thrombosis or pulmonary embolus in the 6 months prior to screening.
Subject has known active tuberculosis.
Subject has undergone thoracotomy with pulmonary resection (except for sub-lobar resection).
Subject has resting pulse < 40 bpm or > 100 bpm; resting systolic blood pressure > 160 mm Hg or < 90 mm Hg; resting diastolic blood pressure > 100 mm Hg at screening. These assessments may be repeated once at the investigator's discretion (within the screening window).
Subject desaturates to SpO2 < 85% for at least 1 minute on screening IET.
Subject has a limitation of exercise performance as a result of factors other than fatigue or exertional dyspnea/shortness of breath (considered to be due to COPD), such as arthritis in the leg, angina pectoris, heart failure, claudication or morbid obesity.
Subject has a CWR cycle ergometry endurance time less than 4 or greater than 8 minutes after WR adjustment procedures.
Subject has used the following drugs within 14 days prior to day -1:
- Strong cytochrome P450 (CYP)3A4 inhibitor (e.g., itraconazole, clarithromycin).
- Strong CYP3A4 inducer (e.g., barbiturates, rifampin).
Subject has hemoglobin (Hb) concentration below 10.0 g/dL at screening.
Subject has a cancer requiring treatment currently or in the past 3 years (except primary nonmelanoma skin cancer, carcinoma in situ or cancers that have an excellent prognosis such as early stage breast or prostate cancer).
Subject giving a history of asthma, allergic rhinitis or atopy shall be evaluated by the investigator to determine whether the subject's predominant diagnosis is COPD rather than asthma.
Subject has neurological conditions or neuromuscular diseases that are causing impaired muscle function or mobility.
Subject has a current diagnosis of schizophrenia, other psychotic disorders or bipolar disorder.
Subject in the active phase of pulmonary rehabilitation or had completed pulmonary rehabilitation or exercise training within the 13 weeks prior to screening.
Subject has severe and/or uncontrolled medical conditions that could interfere with the study (e.g., severe neurological deficit after stroke, developed diabetic peripheral neuropathy, respiratory diseases requiring daytime supplemental oxygen, infection, gastrointestinal disorder, uncontrolled pain or any other non-stable illness) as judged by the medical investigator.
Subject has a known history of positive test for hepatitis B surface antigen (HBsAg) or hepatitis C antibody or history of a positive test for human immunodeficiency virus (HIV) infection.
Subject has a history of alcoholism or drug/chemical substance abuse within 2 years prior to screening.
Subject has used any medications known to affect physical function or muscle mass including androgen supplements, anti-androgens (such as luteinizing hormone-releasing hormone [LHRH] agonists), anti-estrogen (tamoxifen, etc.), recombinant human growth hormone (rhGH), insulin, oral beta adrenergic agonists, megestrol acetate, dronabinol, metformin or other drugs which, in the opinion of the investigator, might influence physical function or muscle mass within 6 weeks prior to screening.
Subject has participated in any interventional clinical study or has been treated with any investigational drugs within 28 days or 5 half-lives whichever is longer, prior to the initiation of screening.
Subject has any other condition that in the opinion of the investigator precludes the subject's participation in the trial.

Name	Affiliation	Role
Senior Medical Director	Astellas Pharma Global Development, Inc.	Study Director

Facility	Status	City	State	ZIP	Country	Contacts
Site US10001		Torrance	California	90502	United States
Site US10003

Label	URL
Link to results on the Astellas Clinical Study Results website.	View source

ID	Title	Description
FG000	CK-2127107 1000 mg, Then Placebo	Participants received CK-2127107 500 mg, orally, twice daily for 2 weeks in treatment period 1 followed by matching placebo orally, twice daily for 2 weeks in treatment period 2. A washout period of 2 weeks was maintained between the two treatment periods.
FG001

Type	Includes Protocol	Includes SAP	Includes ICF	Document Label	Document Date	Document Uploaded Date	Document File Name
Prot	Yes	No	No	Study Protocol	Nov 29, 2017	Nov 12, 2020

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Change From Period Baseline at Week 2 in Constant Work Rate (CWR) Endurance Time Relative to Placebo

The CWR defines how long it takes until the participant reaches symptom limitations while simultaneously being monitored and is called "CWR time to intolerance," which determined the "CWR endurance time". Positive change indicates an improvement from baseline (i.e., a favorable outcome).

The full analysis set (FAS) consisted of all participants who were randomized and received ≥ 1 dose of study drug and had ≥ 1 baseline measurement and 1 post baseline measurement within a period. FAS population with available data at each specified time point.

Posted

Least Squares Mean

Standard Error

seconds

Baseline and week 2 of each treatment period

ID	Title	Description
OG000	Placebo	Participants received matching placebo orally, twice daily for 2 weeks in treatment periods 1 and 2.
OG001	CK-2127107	Participants received CK-2127107 500 mg orally twice daily for 2 weeks in treatment periods 1 and 2.

Units	Counts
Participants	OG00032 OG00135

Title

Denominators

Categories

Title	Measurements
	OG000-1.4± 22.2 OG001-13.4± 21.2

Group IDs	Group Description	Statistical Method	Statistical Comment	P-Value	P-Value Comment	Parameter Type	Parameter Value	Dispersion Type	Dispersion Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	CI Lower Limit Comment	CI Upper Limit Comment	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type	Non-Inferiority Comment	Other Analysis Description
OG000 OG001	Least square means (LSMeans), LSMean difference of CK-2127107 minus placebo, and 90% confidence intervals are based on a mixed effect model with treatment and period as fixed effects, subject as a random effect, and a compound symmetry covariance structure.	Mixed Models Analysis		0.734	Statistical comparison was performed at a 2-sided 0.10 significance level.	LSMean difference	-12.0			2-Sided	90	-71.2	47.2					Superiority

Secondary

Change From Period Baseline at Week 2 in Oxygen Uptake (VO2)

VO2 was defined as volume of O2 extracted from inspired air in a given period of time. VO2 was reported at isotime and peak exercise during CWR test.

FAS population with available data at each specified time point.

Posted

Least Squares Mean

Standard Error

Liter per minute (L/min)

Baseline and week 2 of each treatment period

ID	Title	Description
OG000	Placebo	Participants received matching placebo orally, twice daily for 2 weeks in treatment periods 1 and 2.
OG001	CK-2127107	Participants received CK-2127107 500 mg orally twice daily for 2 weeks in treatment periods 1 and 2.

Units	Counts
Participants	OG000

Secondary

Change From Period Baseline at Week 2 in Ventilation (VE)

VE was defined as volume of gas exhaled from the lungs in 1 minute, also called 'ventilation' or 'minute ventilation. VE was reported at isotime and peak exercise during CWR test.

FAS population with available data at each specified time point.

Posted

Least Squares Mean

Standard Error

L/min

Baseline and week 2 of each treatment period

ID	Title	Description
OG000	Placebo	Participants received matching placebo orally, twice daily for 2 weeks in treatment periods 1 and 2.
OG001	CK-2127107	Participants received CK-2127107 500 mg orally twice daily for 2 weeks in treatment periods 1 and 2.

Units	Counts
Participants	OG000

Secondary

Change From Period Baseline at Week 2 in Ventilatory Equivalent for Carbon Dioxide (VE/VCO2)

VE/VCO2 was a ratio of VE to VCO2. It is a dimensionless quantity. This ratio indicates how many liters of air exhaled were breathed to eliminate 1 liter of CO2. VE/VCO2 was reported at isotime and peak exercise during CWR test.

FAS population with available data at each specified time point.

Posted

Least Squares Mean

Standard Error

ratio

Baseline and week 2 of each treatment period

ID	Title	Description
OG000	Placebo	Participants received matching placebo orally, twice daily for 2 weeks in treatment periods 1 and 2.
OG001	CK-2127107	Participants received CK-2127107 500 mg orally twice daily for 2 weeks in treatment periods 1 and 2.

Units	Counts
Participants	OG000

Secondary

Change From Period Baseline at Week 2 in Inspiratory Capacity (IC) Change From Peak to Rest

IC was defined as the volume of air that can be inspired after a normal expiration; it is the sum of the tidal volume (VT) and the IRV.

FAS population with available data each specified time point.

Posted

Least Squares Mean

Standard Error

Liters

Baseline and week 2 of each treatment period

ID	Title	Description
OG000	Placebo	Participants received matching placebo orally, twice daily for 2 weeks in treatment periods 1 and 2.
OG001	CK-2127107	Participants received CK-2127107 500 mg orally twice daily for 2 weeks in treatment periods 1 and 2.

Units	Counts
Participants	OG000

Secondary

Change From Period Baseline at Week 2 in Perceived Exertion for Dyspnea and Leg Discomfort (BORG CR10)

The Borg Scale (Borg CR10) is a simple 10-item method of rating perceived exertion and collects information on perceived exertion in an individual's rating of exercise intensity. Participants were asked to use this scale to rate the intensity of their breathing and leg discomfort before, during, and after exercise. Scores range from 0 (Complete Rest) to 10 (Extremely Hard (almost maximal)). BORG CR10 was reported at isotime and peak exercise during CWR test.

FAS population with available data at each specified time point.

Posted

Least Squares Mean

Standard Error

units on a scale

Baseline and week 2 of each treatment period

ID	Title	Description
OG000	Placebo	Participants received matching placebo orally, twice daily for 2 weeks in treatment periods 1 and 2.
OG001	CK-2127107	Participants received CK-2127107 500 mg orally twice daily for 2 weeks in treatment periods 1 and 2.

Units	Counts
Participants

Secondary

Change From Period Baseline at Week 2 in Respiratory Exchange Ratio (RER)

The respiratory exchange ratio is equal to the VCO2 / VO2 [RER = VCO2 (L/min) / VO2 (L/min)]. RER was reported at isotime and peak exercise during CWR test.

FAS population with available data at each specified time point.

Posted

Least Squares Mean

Standard Error

ratio

Baseline and week 2 of each treatment period

ID	Title	Description
OG000	Placebo	Participants received matching placebo orally, twice daily for 2 weeks in treatment periods 1 and 2.
OG001	CK-2127107	Participants received CK-2127107 500 mg orally twice daily for 2 weeks in treatment periods 1 and 2.

Units	Counts
Participants	OG000

Secondary

Change From Period Baseline at Week 2 in Carbon Dioxide Output (VCO2)

VCO2 was defined as volume of CO2 exhaled from the body per unit of time; also called the rate of elimination of CO2. VCO2 was reported at isotime and peak exercise during CWR test.

FAS population with available data at each specified time point.

Posted

Least Squares Mean

Standard Error

L/min

Baseline and week 2 of each treatment period

ID	Title	Description
OG000	Placebo	Participants received matching placebo orally, twice daily for 2 weeks in treatment periods 1 and 2.
OG001	CK-2127107	Participants received CK-2127107 500 mg orally twice daily for 2 weeks in treatment periods 1 and 2.

Units	Counts
Participants	OG000

Secondary

Change From Period Baseline at Week 2 in End-tidal PCO2 (PETCO2)

PETCO2 was defined as partial pressure of carbon dioxide in the expired gas at the end of an exhalation. This represents the mean partial pressure of carbon dioxide in the pulmonary alveoli. PETCO2 was reported at isotime and peak exercise during CWR test.

FAS population with available data at each specified time point.

Posted

Least Squares Mean

Standard Error

mmHg

Baseline and week 2 of each treatment period

ID	Title	Description
OG000	Placebo	Participants received matching placebo orally, twice daily for 2 weeks in treatment periods 1 and 2.
OG001	CK-2127107	Participants received CK-2127107 500 mg orally twice daily for 2 weeks in treatment periods 1 and 2.

Units	Counts
Participants	OG000

Secondary

Change From Period Baseline at Week 2 in End-tidal PO2 (PETO2)

PETO2 was defined as Partial pressure of oxygen in the expired gas at the end of an exhalation. This represents the mean partial pressure of oxygen in the pulmonary alveoli. PETO2 was reported at isotime and peak exercise during CWR test.

FAS population with available data at each specified time point.

Posted

Least Squares Mean

Standard Error

mmHg

Baseline and week 2 of each treatment period

ID	Title	Description
OG000	Placebo	Participants received matching placebo orally, twice daily for 2 weeks in treatment periods 1 and 2.
OG001	CK-2127107	Participants received CK-2127107 500 mg orally twice daily for 2 weeks in treatment periods 1 and 2.

Units	Counts
Participants	OG000

Secondary

Change From Period Baseline at Week 2 in Tidal Volume (VT)

VT was defined as tidal volume is the volume of gas exhaled in each respiratory cycle. Tidal volume is typically measured as an average value over several respiratory cycles, and is expressed in liters. VT was reported at isotime and peak exercise during CWR test.

FAS population with available data at each specified time point.

Posted

Least Squares Mean

Standard Error

Liters

Baseline and week 2 of each treatment period

ID	Title	Description
OG000	Placebo	Participants received matching placebo orally, twice daily for 2 weeks in treatment periods 1 and 2.
OG001	CK-2127107	Participants received CK-2127107 500 mg orally twice daily for 2 weeks in treatment periods 1 and 2.

Units	Counts
Participants	OG000

Secondary

Change From Period Baseline at Week 2 in Breathing Frequency (Bf)

Bf was defined as the number of breaths (i.e., an entire inspiratory and expiratory respiratory cycle) per minute. Bf was reported at isotime and peak exercise during CWR test.

FAS population with available data at each specified time point.

Posted

Least Squares Mean

Standard Error

Breaths/min

Baseline and week 2 of each treatment period

ID	Title	Description
OG000	Placebo	Participants received matching placebo orally, twice daily for 2 weeks in treatment periods 1 and 2.
OG001	CK-2127107	Participants received CK-2127107 500 mg orally twice daily for 2 weeks in treatment periods 1 and 2.

Units	Counts
Participants	OG000

Secondary

Change From Period Baseline at Week 2 in Inspiratory Capacity (IC)

IC was defined as the volume of air that can be inspired after a normal expiration; it is the sum of the VT and the IRV. IC was reported at isotime and peak exercise during CWR test.

FAS population with available data at each specified time point.

Posted

Least Squares Mean

Standard Error

Liters

Baseline and week 2 of each treatment period

ID	Title	Description
OG000	Placebo	Participants received matching placebo orally, twice daily for 2 weeks in treatment periods 1 and 2.
OG001	CK-2127107	Participants received CK-2127107 500 mg orally twice daily for 2 weeks in treatment periods 1 and 2.

Units	Counts
Participants	OG000

Secondary

Change From Period Baseline to Week 2 in Inspiratory Reserve Volume (IRV)

The Inspiratory reserve volume was equal to VT - IC measured in liters [IRV (L) = VT (L) - IC (L)]. IRV was reported at isotime and peak exercise during CWR test.

FAS population with available data at each specified time point.

Posted

Least Squares Mean

Standard Error

Liters

Baseline and week 2 of each treatment period

ID	Title	Description
OG000	Placebo	Participants received matching placebo orally, twice daily for 2 weeks in treatment periods 1 and 2.
OG001	CK-2127107	Participants received CK-2127107 500 mg orally twice daily for 2 weeks in treatment periods 1 and 2.

Units	Counts
Participants	OG000

Secondary

Change From Period Baseline at Week 2 in Ventilatory Reserve (VE/MVV)

VE/MVV provides the rate of expired ventilation to the capacity. VE/MVV was reported at isotime and peak exercise during CWR test.

FAS population with available data at each specified time point.

Posted

Least Squares Mean

Standard Error

percentage of expired ventilation

Baseline and week 2 of each treatment period

ID	Title	Description
OG000	Placebo	Participants received matching placebo orally, twice daily for 2 weeks in treatment periods 1 and 2.
OG001	CK-2127107	Participants received CK-2127107 500 mg orally twice daily for 2 weeks in treatment periods 1 and 2.

Units	Counts
Participants	OG000

Secondary

Change From Period Baseline at Week 2 in Heart Rate (HR)

HR was reported at isotime and peak exercise during CWR test.

FAS population with available data at each specified time point.

Posted

Least Squares Mean

Standard Error

Beats/min

Baseline and week 2 of each treatment period

ID	Title	Description
OG000	Placebo	Participants received matching placebo orally, twice daily for 2 weeks in treatment periods 1 and 2.
OG001	CK-2127107	Participants received CK-2127107 500 mg orally twice daily for 2 weeks in treatment periods 1 and 2.

Units	Counts
Participants	OG000

Secondary

Change From Period Baseline at Week 2 in Systolic Blood Pressure (SBP)

SBP was reported at isotime and peak exercise during CWR test.

FAS population with available data each specified time point.

Posted

Least Squares Mean

Standard Error

mmHg

Baseline and week 2 of each treatment period

ID	Title	Description
OG000	Placebo	Participants received matching placebo orally, twice daily for 2 weeks in treatment periods 1 and 2.
OG001	CK-2127107	Participants received CK-2127107 500 mg orally twice daily for 2 weeks in treatment periods 1 and 2.

Units	Counts
Participants	OG000

Secondary

Change From Period Baseline at Week 2 in Diastolic Blood Pressure (DBP)

DBP was reported at isotime and peak exercise during CWR test.

FAS population with available data at each specified time point.

Posted

Least Squares Mean

Standard Error

mmHg

Baseline and week 2 of each treatment period

ID	Title	Description
OG000	Placebo	Participants received matching placebo orally, twice daily for 2 weeks in treatment periods 1 and 2.
OG001	CK-2127107	Participants received CK-2127107 500 mg orally twice daily for 2 weeks in treatment periods 1 and 2.

Units	Counts
Participants	OG000

Secondary

Change From Period Baseline at Week 2 in Arterial Oxygen Saturation From Pulse Oximetry (SpO2)

SPO2 was defined as the noninvasive estimation of arterial hemoglobin (Hb) oxygen saturation, using a device that utilizes the combined principles of spectrophotometry and pulse plethysmography. SPO2 was reported at isotime and peak exercise during CWR test.

FAS population with available data at each specified time point.

Posted

Least Squares Mean

Standard Error

percentage of oxygen saturation

Baseline and week 2 of each treatment period

ID	Title	Description
OG000	Placebo	Participants received matching placebo orally, twice daily for 2 weeks in treatment periods 1 and 2.
OG001	CK-2127107	Participants received CK-2127107 500 mg orally twice daily for 2 weeks in treatment periods 1 and 2.

Units	Counts
Participants	OG000

Secondary

Change From Period Baseline at Week 2 in Forced Vital Capacity (FVC)

Change From Period Baseline in FVC was reported.

FAS population with available data at each specified time point.

Posted

Least Squares Mean

Standard Error

Liters

Baseline and week 2 of each treatment period

ID	Title	Description
OG000	Placebo	Participants received matching placebo orally, twice daily for 2 weeks in treatment periods 1 and 2.
OG001	CK-2127107	Participants received CK-2127107 500 mg orally twice daily for 2 weeks in treatment periods 1 and 2.

Units	Counts
Participants	OG000

Secondary

Change From Period Baseline at Week 2 in Forced Expiratory Volume 1 (FEV1)

Change From Period Baseline in FEV1 was reported.

FAS population with available data at each specified time point.

Posted

Least Squares Mean

Standard Error

Liters

Baseline and week 2 of each treatment period

ID	Title	Description
OG000	Placebo	Participants received matching placebo orally, twice daily for 2 weeks in treatment periods 1 and 2.
OG001	CK-2127107	Participants received CK-2127107 500 mg orally twice daily for 2 weeks in treatment periods 1 and 2.

Units	Counts
Participants	OG000

Secondary

Change From Period Baseline at Week 2 in FVC/FEV1 Ratio

Change From Period Baseline in FVC/FEV1 Ratio was reported.

FAS population with available data at each specified time point.

Posted

Least Squares Mean

Standard Error

ratio

Baseline and week 2 of each treatment period

ID	Title	Description
OG000	Placebo	Participants received matching placebo orally, twice daily for 2 weeks in treatment periods 1 and 2.
OG001	CK-2127107	Participants received CK-2127107 500 mg orally twice daily for 2 weeks in treatment periods 1 and 2.

Units	Counts
Participants	OG000

Secondary

Change From Period Baseline at Week 2 in Activation of Accessory Respiratory Muscles

Activation of accessory respiratory muscles was assessed by electromyogram. Data was reported at peak and isotime.

FAS population with available data at each specified time point.

Posted

Least Squares Mean

Standard Error

percentage of activation

Baseline and week 2 of each treatment period

ID	Title	Description
OG000	Placebo	Participants received matching placebo orally, twice daily for 2 weeks in treatment periods 1 and 2.
OG001	CK-2127107	Participants received CK-2127107 500 mg orally twice daily for 2 weeks in treatment periods 1 and 2.

Units	Counts
Participants	OG000

Secondary

Number of Participants With Treatment Emergent Adverse Events

TEAEs were defined as any AE that started or worsened in severity after the first dose of study drug up to 14 days after the last dose of study drug. An AE was defined as any untoward medical occurrence in a participant administered a study drug or who had undergone study procedures and did not necessarily have a causal relationship with this treatment. An AE could therefore be any unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An abnormality identified during a medical test (e.g., laboratory parameter, vital sign, ECG data, physical examination) an AE only if the abnormality meets 1 of the following criteria: Induces clinical signs or symptoms, Requires active intervention, Requires interruption or discontinuation of study drug, The abnormality or test value is clinically significant in the opinion of the inves

SAF population

Posted

Number

Participants

From first dose of study drug up to 14 days after last dose of study drug (8 weeks)

ID	Title	Description
OG000	Placebo	Participants received matching placebo orally, twice daily for 2 weeks in treatment periods 1 and 2.
OG001	CK-2127107	Participants received CK-2127107 500 mg orally twice daily for 2 weeks in treatment periods 1 and 2.

Secondary

Plasma Concentration of CK-2127107 at Day 1 Predose, Day 14 Lowest Concentration (Ctrough), and Day 14 Concentration Predose 6 Hours (C6h)

Plasma concentration of CK-2127107 was reported.

The pharmacokinetic analysis set (PKAS) consisted of the administered population for which ≥ 1 quantifiable plasma trough concentration or concentration at 6 hours was available for CK-2127107, or its metabolite CK-2127106.

Posted

Mean

Standard Deviation

Nanogram per milliliter (ng/mL)

Day 1 predose, day 14 Ctrough, day 14 C6h

ID	Title	Description
OG000	CK-2127107	Participants received CK-2127107 500 mg orally twice daily for 2 weeks in treatment periods 1 and 2.

Units	Counts
Participants	OG000

Secondary

Plasma Concentration of CK-2127106 (Metabolite of CK-2127107) at Day 1 Predose, Day 14 Ctrough, Day 14 C6h

Plasma concentration of CK-2127106 (metabolite of CK-2127107) was reported.

PKAS population

Posted

Mean

Standard Deviation

ng/mL

Day 1 predose, day 14 Ctrough, day 14 C6h

ID	Title	Description
OG000	CK-2127107	Participants received CK-2127107 500 mg orally twice daily for 2 weeks in treatment periods 1 and 2.

Units	Counts
Participants	OG00033

ID	Title	Description
BG000	CK-2127107 1000mg, Then Placebo	Participants received CK-2127107 500 mg, orally, twice daily for 2 weeks in treatment period 1 followed by matching placebo orally, twice daily for 2 weeks in treatment period 2. A washout period of 2 weeks will be maintained between the two treatment periods.
BG001	Placebo, Then CK-2127107 1000mg	Participants received matching placebo orally, twice daily for 2 weeks in treatment period 1 followed by CK-2127107 500 mg, orally, twice daily for 2 weeks in treatment period 2. A washout period of 2 weeks will be maintained between the two treatment periods.
BG002	Total	Total of all reporting groups

ID	Title	Description	Deaths (Affected)	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Placebo	Participants received matching placebo orally, twice daily for 2 weeks in treatment periods 1 and 2.	0	41	1	41	1	41
EG001	CK-2127107	Participants received CK-2127107 500 mg orally twice daily for 2 weeks in treatment periods 1 and 2.	0	42	2	42	3	42

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Renal cell carcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	MedDRA 17.1	Systematic Assessment	EG0000 events0 affected41 at risk EG0011 events1 affected42 at risk
IIIrd nerve paralysis	Nervous system disorders	MedDRA 17.1	Systematic Assessment	EG0000 events0 affected41 at risk EG0011 events1 affected42 at risk
Haematuria	Renal and urinary disorders	MedDRA 17.1	Systematic Assessment	EG0001 events1 affected41 at risk EG0010 events0 affected42 at risk

ID	Term
D008173	Lung Diseases, Obstructive
D008171	Lung Diseases
D012140	Respiratory Tract Diseases
D002908	Chronic Disease
D020969	Disease Attributes
D010335	Pathologic Processes
D013568	Pathological Conditions, Signs and Symptoms